Practices

Life Sciences

 

Build on Your Ideas.

Are you a biotech firm? A pharmaceutical or medical device company? A global life sciences leader? A start-up with a great idea under wraps? In our view, size doesn’t define you; mind set and actions do. You’re driven to make a difference and that drive makes you an ideal match for Mintz Levin. From the word “Go” to the words “Go public” and beyond, Mintz Levin lawyers provide business-building counsel based on a thorough understanding of your industry.

Companies like Biogen Idec turned to us at the birth of the industry in the 1970s. Today, ours is one of the deepest and largest life science practices in the country. This means that you can firmly rely on the legal resources you need at Mintz Levin. More importantly, you’ll gain an informed perspective on your business, your issues, and the best way to build and expand a sustainable enterprise around your ideas. Our combination of skills, experience, industry relationships, and like-minded thinking draws life science organizations like yours to Mintz Levin every day.

We represent biotechnology, medical device, and pharmaceutical companies, venture capital firms and investment banks, as well as research institutes and institutions of higher education located throughout the U.S., Europe, Asia, and the Middle East, in a broad range of transactional, regulatory, counseling, and intellectual property matters. Our Life Sciences service teams include attorneys, senior professionals, and PhDs with scientific or industry-specific experience and knowledge of finance, management and systems, clinical strategy, regulatory affairs, licensing, patents, corporate transactions, immigration, tax, manufacturing, accounting, product economics, and real estate.

From startup companies with a new idea to large public companies with products on the market, Mintz Levin attorneys will help:

  • Complete mergers, acquisitions, and innovative financings.
  • Defend intellectual property and product liability lawsuits.
  • Navigate product launches.
  • Negotiate strategic collaborations and alliances.
  • Protect your intellectual property.
  • Raise capital.
  • Recruit and retain the best possible workforce while you stay focused on achieving your corporate goals.

Work Through Clinical and Other Trials.

Innovation requires a single-minded focus that can be challenging, especially when you have a company to run and a workforce to manage. But with research and development come challenges and opportunities that can require just as much focus and be equally rewarding. You need to create and protect intellectual property, raise capital, manage operations, build and expand facilities, recruit and retain talent, resolve disputes, enter into complex partnerships, and more. However, nurturing the health and well-being of your product development pipeline and its place in the market is your first priority.

To help you work through these challenges, clients turn to high-performing, interdisciplinary teams of Mintz Levin corporate, finance, IP licensing, real estate, litigation, and regulatory lawyers as well as professionals from our government affairs and PR affiliate, ML Strategies.

Do a Great Deal.

In your industry, capital and other transactions drive the engine, and R&D investments come with long-term and unpredictable returns. The more capital you have, the quicker you can move your products to market, so as your company expands you may be involved in many financings. You may complete venture rounds, mergers and acquisitions, enter into joint ventures and licensing agreements—and you may need to do multiple transactions at the same time. But each one is critical and needs to be executed efficiently while the opportunity is still in play. We do those deals every day at Mintz Levin. Which means we can help you find compatible partners, compare financing options, avoid unnecessary risks, and keep your wits about you to tackle the next deal—and the next.

With more than 400 Life Science clients, we provide comprehensive advice to both mature companies as well as to innovative pioneers. Mintz Levin offers you a view into the best practices and lessons learned by those on all sides of the rapidly-evolving Life Science landscape.

Sponsorships and Memberships

Mintz Levin‘s commitment to Life Sciences includes sponsorship of events and various memberships:

  • AdvaMed - Member
  • Astia NY Funding Series - Sponsor
  • BayBio, Pantheon Awards - Event Sponsor
  • BIO (Biotechnology Industry Organization) - Member, Sponsor BIO 2008
  • BIOCOM - Sponsor, CEO Summit and Breakfast Series
  • BSCP Evening of Hope - Sponsor
  • California Health Institute
  • Convergence Life Science Forum, Martha’s Vineyard, MA June 2008 - Sponsors, Fall 2007 and 2008 Life Science Dinners
  • Enterprise Tuesday, London, UK - Sponsor
  • Food and Drug Law Institute
  • Helix Award,  Sponsors ’07, ’08, ’09 — Founded by the Center for Biotechnology and Stony    Brook University in 1996 and awarded annually in partnership with the Biotechnology Industry Organization (BIO), the award recognizes biotechnology companies that have distinguished themselves by setting a singular standard of corporate leadership as reflected in performance in the areas of scientific innovation and company growth.
  • London Biotechnology Network 2008
  • MassMedic - Member
  • Medical Device Manufacturers Association - Member
  • MIT Enterprise Forum - Member
  • Regional Bioscience Association memberships including: MBC (MA), NYBA (NY), BIOCOM (San Diego), BayBIO (Northern CA), CHI (CA), MassMedic (MA), Council of State Bioscience Associations, Legal Hours at University of California at San Francisco, Astia Entrepreneur Program
  • Wireless Life Sciences Association - Member

Pro Bono Services

In recent years, a member of the Firm’s Corporate practice has worked with the New York Biotechnology Association, Inc., a not-for-profit trade association dedicated to the development and growth of New York State based biotechnology related industries and institutions. The Mintz Levin attorney assisted in the presentation and preparation of educational programs and has provided advice to the Association on governance matters.

Please click here for a pdf of our Life Science Counsel brochure.

Please click here for a pdf of our MedTech Team Representation from IP to IPO brochure.

 

Related Practices

1

News

1

1
1
1

1

Events

1

1
1
1

1



View all events

Publications

FDA Releases Strategic Priorities That Will Guide Agency Through 2015

4/29/2011

BNA's Pharmaceutical Law & Industry

Life Sciences Alert: FDA Releases Criteria for Responsible Officer Prosecutions

2/14/2011



Life Sciences Advisory: FDA to Begin Revamping the 510(k) Medical Device Review Program

1/25/2011



PLIR Advisory Board Sees Biosimilars, Enforcement Among Top Concerns for 2011

1/21/2011

BNA's Pharmaceutical Law & Industry

Foreign Corrupt Practices Act (FCPA) Alert: The DOJ's FCPA Crackdown on the Pharmaceutical and Medical Devices Industry

9/23/2010



Life Sciences Advisory: New Proposed HIPAA Rules May Benefit Researchers

8/9/2010



Health Care Reform Advisory: Reminder: Applications under the $1 Billion Qualifying Therapeutic Discovery Project Program Due July 21, 2010

6/30/2010



Health Care Reform Advisory: How to Apply for a Billion-Dollar Tax Credit and Grant Opportunity - New Guidance from the IRS

5/25/2010



Health Care Reform Advisory: Update on the Billion-Dollar Tax Credit and Grant Opportunity: What Life Sciences Companies Can Do Now to Prepare

4/29/2010



Health Care Reform Advisory: Billion-Dollar Tax Credit and Grant Opportunity for Life Sciences Companies

4/5/2010



Life Sciences Industry Extra: Federal Funding Opportunity for Orphan Products

1/12/2009



Life Sciences Alert: Biotechnology Industry Executives Propose Bailout for Struggling Companies

12/12/2008



Health Law Alert: PhRMA Issues New Marketing Code Effective January 2009

7/10/2008



Life Sciences Industry Extra: Mintz Levin's Joel Papernik to Speak at BIO International Convention

5/29/2008



Privacy and Security Alert: The FTC Approves Long-Awaited CAN-SPAM Discretionary Rule

5/13/2008



Life Sciences Industry Extra: Mintz Levin's Joel Papernik to Speak at NYBA Annual Meeting

5/6/2008



Business and Finance Alert: Important Q&A on the Effect of New Section 409A of the Internal Revenue Code on Stock Options and Other Types of Equity Grants

12/14/2005



Intellectual Property Client Alert: Supreme Court Expands Safe Harbor Exemption Definition for Preclinical Research

7/20/2005



Best Practices for Home Health Care Association Financial Managers, a Presentation by Mintz Levin Health Attorney Ellen Janos

10/14/2004



Health Presentation: Fraud and Abuse Issues Involving Pharmaceutical Products and Medical Devices

9/27/2004



Health Memorandum: Medicare Prescription Drug Improvement and Modernization Act of 2003 - An Analysis for Medical Device Manufacturers

12/19/2003



Public Finance Advisory: After the Bond Closing - Obligations of Non-Profit Borrowers

12/8/2003



Health Advisory: The New Medicare

12/3/2003



Health Alert: Congress Passes Major Medicare Reform Bill

11/26/2003



Immigration Advisory: BCIS, BCBP and BICE Name Change, H-1B Cap, Diversity Visa Program, US-VISIT Program Delays, and more

10/15/2003



Health Advisory: Recently Passed House and Senate Medicare Reform Bills Would Significantly Affect Health Care Providers

7/25/2003



Securities Advisory: Safe Harbor From Definition of "Investment Company"

7/18/2003



Securities Advisory: Improper Influence of Audits and Retention of Auditor Records

6/26/2003



Immigration Advisory: INS Reorganization, H1-B Visa Cap, PERM Regulation, NSEERS, and More

6/16/2003



Health Advisory: New Final HIPAA Regulations Emphasize Flexibility

6/2/2003



Intellectual Property Client Alert: FDA Proposes Changes To Clarify Patent Listing Requirements and 30-Month Stays of Approval Following Submission of Abbreviated New Drug Applications

5/21/2003



Environmental Article: Minimizing Transactional Environmental Risks: Selecting and Managing the Right Environmental Consultant

5/15/2003



Health Advisory: OIG Issues New Guidance on Pharmacy Issues and Joint Ventures

5/14/2003



Securities Advisory: SEC Proposes Safe Harbor from Definition of Investment Company for Certain Research and Development Companies

1/15/2003



Intellectual Property Advisory: Patent Appeals Court Ruling Highlights Potential Pitfalls of Over-reliance on Provisional Patent Applications

8/27/2002



Litigation Publication: Class Action Newsletter

5/15/2002



Intellectual Property Client Alert: U.S. Patent Court Rules on Deposit of Biological Organisms and the Written Description Requirement of the Patent Law

5/1/2002



Intellectual Property Advisory: Payment for New Health Care Technologies- The Long and Winding Road

3/1/2002



Intellectual Property Advisory: Medical Device Patents- An Important Business Asset

3/1/2002



Business Advisory: Best Strategies for Selling a Medical Device Business

3/1/2002



Bioinformatics Advisory: Business and Legal Aspects of Open Source Software for Bioinformatics

2/1/2002



Intellectual Property Advisory Bioinformatics Patents- Challenges and Opportunities

11/1/2001



Intellectual Property Advisory: Patent Strategies for Israeli Companies Doing Business in the United States

9/1/2001



Intellectual Property Client Alert: Supreme Court Grants Certiorari in Festo Patent Matter- Potential Doctrine of Equivalents Ramifications

6/1/2001



Health Advisory: Medicaid Drug Rebate Law Celebrates First Decade as Federal Prosecutors Provide First Close Look at Implementation

12/1/2000



Health Advisory: HCFA, Supreme Court and the White House

6/1/2000



Health Advisory: Focus- Human Clinical Trials- Clinical Trial Issues Suddenly Loom

6/1/2000



Health Advisory: FDA Announces New Regulatory Requirements for Certain PET Drugs; All Production to be Treated as Manufacturing

4/1/2000



Health Advisory: Internet Pharmacies and Health Care

2/1/2000



Resources

Current DevelopMintz

Center for Health Law & Policy
Bringing industry leaders, policy makers, and the best legal minds together to improve the health care system. >> Read more

Health Care Reform:
Analysis & Perspectives

>> Click here for details

Related Clients

  • Alphatec Spine
  • Amedica Corp.
  • Archemix Corporation
  • ARIAD Pharmaceuticals, Inc.
  • Ascent Therapeutics, Inc.
  • Aureon Laboratories
  • Biogen IDEC Inc.
  • Bioprocessors Corporation
  • Caliper Life Sciences
  • CLS Pharmaceuticals
  • Coley Pharmaceutical Group
  • Cyclacel Pharmaceuticals, Inc.
  • Eli Lilly & Co.
  • HealthpointCapital
  • ImmunoGen, Inc.
  • Kinex Pharmaceuticals
  • Myriad Genetics
  • Orchid Cellmark
  • OSI Pharmaceuticals Inc.
  • Oxford Bioscience Partners
  • Panacos Pharmaceuticals, Inc.
  • Paratek
  • Precision Pulsus, Inc.
  • Pulmatrix Inc.
  • Qiagen GmbH
  • Response Genetics, Inc.
  • Rosetta Genomics
  • Synvista Therapeutics, Inc.
  • TissueLink
  • Trident Pharmaceuticals Inc.
  • Tutogen
  • Vertex Pharmaceuticals, Inc.